Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Paroxysmal Supraventricular Tachycardia

In brief

This was a three-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil nasal spray (NS) self-administered by participants who experienced an episode of paroxysmal supraventricular tachycardia (PSVT) in an at-home setting. NODE-301 Part 1 included participants that received the randomized study drug to treat an episode of PSVT until the 150th positively adjudicated PSVT episode. Part 2 (also referred as the RAPID study) included participants that did not receive the randomized study drug in Part 1 and newly enrolled participants until the 180th positively adjudicated PSVT episode in Part 2. The study continued for approximately 6 months after the 180th positively adjudicated PSVT episode in Part 2 and this extension is referred to as Part 3 (also referred to as RAPID Extension).

Key facts

Study ID

NCT03464019

Run by

Milestone Pharmaceuticals Inc.

People needed

1097

Starts

2018-06-18

Expected to finish

2023-01-20

Last updated by the study team

2024-07-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who met all of the following criteria were eligible to participate in the study:
• Male or female participants at least 18 years of age;
• Electrographically documented history of PSVT (e.g., electrocardiogram [ECG] obtained during an episode of PSVT, Holter monitoring, loop recorder, etc). If participant had a prior ablation for PSVT, participant had to have documented ECG evidence of PSVT post-ablation;
• History of sustained episodes of PSVT (i.e., typically lasting approximately 20 minutes or longer);
• Females of childbearing potential who were sexually active with a male partner who were not surgically sterile (i.e., vasectomy) had to agree to use a highly effective form of contraception from the time of signed informed consent until 30 days after the last administration of study drug. Females of childbearing potential had to have a negative serum pregnancy test result at the Screening Visit and at the Final Study Visit, a negative urine pregnancy test at the Test Dose Randomization Visit and had to use a highly effective form of contraception between the visits.
• The following categories defined females who were NOT considered to be of childbearing potential:
• Premenopausal females with 1 of the following:
• Documented hysterectomy,
• Documented bilateral salpingectomy or tubal ligation; or
• Documented bilateral oophorectomy, or
• Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause;
• Male participants, except those who were surgically sterile, had to use an approved highly effective form of contraception during the 3 days after any study drug administration; and
• Signed written informed consent.

You may not qualify if…

• Participants who met any of the following criteria were excluded from participation in the study:
• Systolic blood pressure <90 mmHg after a 5-minute rest in sitting position at the Screening Visit or before the Test Dose. In participants treated with a chronic prophylactic drug for PSVT (e.g., beta-blockers, verapamil, and diltiazem), the drug could be stopped for at least the equivalent of 5 half-lives, participants could be rescreened once, and chronic use of the drug could not be restarted after randomization;
• History of severe symptoms of hypotension, especially syncope, during episodes of PSVT;
• History of atrial arrhythmia that did not involve the AV node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial tachycardia);
• History of allergic reaction to verapamil;
• Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if these drugs were stopped at least the equivalent of 5 half-lives before the Test Dose Randomization Visit;
• Current chronic therapy with oral amiodarone, or had taken oral amiodarone within 30 days prior to the Test Dose Randomization Visit;
• Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval <100 msec, Wolff-Parkinson-White syndrome) on the ECG performed at the Screening Visit or before the Test Dose administration;
• Evidence of a second- or third-degree AV block on the ECG performed at the Screening Visit or before the Test Dose administration;
• History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes, ventricular fibrillation, or ventricular tachycardia);
• Current congestive heart failure defined by the New York Heart Association Class II to IV;
• History of Acute Coronary Syndrome or stroke within 6 months of screening;
• Evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate aminotransferase >3 × the upper limit of normal (ULN) or total bilirubin >2 × ULN at the Screening Visit, unless due to Gilbert syndrome;
• Evidence of End-Stage Renal Disease as determined by an estimated glomerular filtration rate assessed at the Screening Visit of <15 mL/min/1.73m2, or requiring hemodialysis;
• Females who were pregnant or lactating;
• Evidence or history of any significant physical or psychiatric condition including drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of participants, or affect their participation in the study. Additionally, the Investigator had the ability to exclude a participant if for any reason the Investigator judged the participant was not a good candidate for the study or would not be able to follow study procedures;
• Participation in any investigational drug or device study or the use of any investigational drug or device within 30 days of the Screening Visit; or
• Previously enrolled in a clinical trial for etripamil and received study drug during a perceived episode of PSVT.
• Before randomization in the study, all participants received a Test Dose of an etripamil NS dosing regimen (etripamil 70 NS mg in Part 1 and in Parts 2 and 3 an initial dose of etripamil NS 70 mg followed by a second dose of etripamil NS 70 mg not earlier than 10 minutes and not later than 15 minutes after the first dose) to evaluate tolerability and to train participants on the study procedures. Participants who passed the Test Dose were randomized in the NODE-301 (2:1) or RAPID and RAPID Extension (2:1) study. A failure of the Test Dose was considered if participants met any of the following criteria occurring after administration of the either the first or second dose of etripamil NS 70 mg:
• Any symptoms consistent with clinically severe hypotension such as pre-syncope, medically significant lightheadedness, syncope, nausea, or vomiting;
• For participants with a pre-Test Dose Systolic Blood Pressure above 100 mmHg:
• Decrease in SBP ≥40 mmHg after Test Dose; or
• Post-Test Dose SBP <80 mmHg;
• For participants with a pre-Test Dose SBP between 90 mmHg and 100 mmHg (inclusive):
• a) Post-Test Dose SBP <75 mmHg;

Where it is running

• Arkansas Cardiology — Little Rock, Arkansas, United States
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Medvin Clinical Research — Cerritos, California, United States
• North Coast Cardiolog — Encinitas, California, United States
• Titan Medical Research - Oceanside — Encinitas, California, United States
• Los Alamitos Cardiovascular — Los Alamitos, California, United States
• Amicis Research Center - Northridge — Northridge, California, United States
• RESPIRE Research — Palm Springs, California, United States
• South Denver Cardiology Associates, P.C — Littleton, Colorado, United States
• Cardiology Associates of Fairfield County — Norwalk, Connecticut, United States
• FWD Clinical Research — Boca Raton, Florida, United States
• Baptist Health Ambulatory Services d/b/a — Jacksonville, Florida, United States
• United Health Research, LLC — Miami, Florida, United States
• IACT Health — Columbus, Georgia, United States
• Piedmont Heart Institute- Fayetteville — Fayetteville, Georgia, United States
• Piedmont Heart Institute-Fayetteville — Fayetteville, Georgia, United States
• Georgia Arrythmia Consultants&Research Institute — Macon, Georgia, United States
• St. Luke's Idaho Cardiology Associates — Boise, Idaho, United States
• Idaho Catalyst Clinical Research — Idaho Falls, Idaho, United States
• AMITA Health Medical Group Heart & Vascular Elk Grpve Village — Elk Grove Village, Illinois, United States
• Parkview Physicians Group - Cardiology — Fort Wayne, Indiana, United States
• Mercy One Iowa Heart Center — West Des Moines, Iowa, United States
• Clinical Trials of America, LLC - Monroe, LA — West Monroe, Louisiana, United States
• MedStar Health Research Institute - Chesapeake Cardiovascular Associates — Baltimore, Maryland, United States
• Arizona Arrhythmia Research Center — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.